Abstract
Both radiation pneumonitis (RP) and immune checkpoint inhibitor pneumonitis (ICI-p) are toxicities that can occur in stage III NSCLC patients undergoing concurrent chemoradiation (CCRT) followed by durvalumab consolidation. We set out to evaluate potential risk factors for the development of symptomatic pneumonitis in a cohort receiving varied doses of combined CCRT and durvalumab.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
